Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Dankzij 3D-technologie kan nier vaker blijven zitten
aug 2024 | Uro-oncologie